Terence Rabbitts

Professor Terence Rabbitts worked in Cambridge from 1973-2006 in the MRC Laboratory of Molecular Biology. He succeeded Fred Sanger as joint Head of the Division of Protein and Nucleic Acid Chemistry together with the Nobel Laureate César Milstein and later with Sir Greg Winter. He became the Director of the Leeds Institute of Molecular Medicine (2007 to 2012), Professor of Molecular Biology at the Weatherall Institute of Molecular Medicine, University of Oxford in 2012 and will move to the Institute of Cancer Research in March 2020. He has been awarded the Colworth Medal of the Biochemical Society and the CIBA Prize and was elected as a Member of the European Molecular Biology Organization (EMBO) (1981), a Fellow of the Royal Society (FRS) (1987) and a Founder Fellow of the Academy of Medical Sciences (FMedSci) (1998).

He has considerable experience with biotechnology. He was Chairman of the Scientific Advisory Board (SAB) of Cambridge Antibody Technology from its instigation until its Stock Market IPO and Chairman of the SAB of Quadrant Healthcare, until its trade sale to Elan. He was a member of the Domantis SAB until the Company’s acquisition by GSK, a Non-Executive Director of Iclectus for three years and a Non-Executive Director of Aptuscan for three years until its acquisition by Avacta. He was the Chairman of the Scientific Advisory Board of Kymab. He is co-founder of Orbit Discovery and of Quadrucept Bio Ltd and is a member of the SAB of Biosceptre and Avacta Life Sciences.